Related Versus Unrelated Donor Transplantation for High Risk (HiRi) Acute Myeloid Leukemia (AML) in First Complete Remission (CR1)

Allogeneic hematopoietic stem cell transplantation (allo-SCT) from an HLA-identical sibling donor (SIB) is considered the preferred postremission therapy for younger patients with HiRi AML in CR1. The role of allo-SCT from volunteer unrelated donors (VUDs) is less clear and randomized controlled tri...

Full description

Saved in:
Bibliographic Details
Published in:Blood 2007-11, Vol.110 (11), p.169-169
Main Authors: Kienast, Joachim, Kolb, Hans-Jochem, Beelen, Dietrich W., Sauerland, Maria Cristina, Berning, Björna, Reichle, Albrecht, Holler, Ernst, Arnold, Renate, Kolbe, Karin, Staib, Peter, Schwerdtfeger, Rainer, Stelljes, Matthias, Schmid, Christoph, Haferlach, Claudia, Berdel, Wolfgang E., Hiddemann, Wolfgang, Buchner, Thomas
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Allogeneic hematopoietic stem cell transplantation (allo-SCT) from an HLA-identical sibling donor (SIB) is considered the preferred postremission therapy for younger patients with HiRi AML in CR1. The role of allo-SCT from volunteer unrelated donors (VUDs) is less clear and randomized controlled trials addressing this issue do not exist. We performed an observational landmark analysis on parallel cohorts of patients aged
ISSN:0006-4971
1528-0020
DOI:10.1182/blood.V110.11.169.169